戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  decrease complication rates associated with endoscopic therapy.
2 S) have lower rebleeding rates compared with endoscopic therapy.
3 are limited because most have already failed endoscopic therapy.
4 cent hemorrhage (SRH) and decreased need for endoscopic therapy.
5 sult in transfusion-dependent anemia despite endoscopic therapy.
6 every 28 days or standard of care, including endoscopic therapy.
7 % of these examinations, enabling subsequent endoscopic therapy.
8 in relief among people who do not respond to endoscopic therapy.
9 residual colorectal neoplasia after previous endoscopic therapy.
10 e resolution after no more than 12 months of endoscopic therapy.
11 g medical conditions which require immediate endoscopic therapy.
12 ients with T1b disease may also benefit from endoscopic therapy.
13  Forrest grade Ia to IIb ulcers were offered endoscopic therapy.
14  and intravenous proton pump inhibitor after endoscopic therapy.
15 indispensable component following successful endoscopic therapy.
16  in the vast majority of patients undergoing endoscopic therapy.
17  CLE, and the technique may be used to guide endoscopic therapy.
18 omy are recurrent and refractory to standard endoscopic therapy.
19  to a shift in treatment algorithms favoring endoscopic therapy.
20 r stigmata of recent hemorrhage and need for endoscopic therapy.
21 ation-induced telangiectasias is amenable to endoscopic therapy.
22  an emphasis on novel imaging techniques and endoscopic therapies.
23 going resection: esophagectomy, 98.6 months; endoscopic therapy, 77.7 months; chemoradiation, 17.3 mo
24 % vs. 10%, P < 0.01), and to be managed with endoscopic therapy (79% vs. 17%, P < 0.01).
25                                              Endoscopic therapy achieves hemostasis in >90% of bleedi
26 hree or larger than 15 mm) received standard endoscopic therapies and UDCA + CBD stenting (group B) a
27              There was no difference between endoscopic therapy and medical therapy in length of hosp
28 ife-threatening bleeding was unresponsive to endoscopic therapy and other surgical procedures.
29                                              Endoscopic therapy and surgery are treatment options for
30   Rebleeding occurs in 20% of patients after endoscopic therapy, and so can we provide better outcome
31 malignant disease remains controversial, and endoscopic therapies appear promising.
32  the efficacy and safety of pharmacologic or endoscopic therapies as primary prophylaxis or that prev
33                                              Endoscopic therapy as primary or secondary prophylaxis o
34 ne GEP-NET subtypes that are appropriate for endoscopic therapy as well as to understand long-term ou
35 ng patients with achalasia continue to offer endoscopic therapies before recommending operative myoto
36 g Heller myotomy for achalasia, 154 received endoscopic therapy before being referred for surgery (10
37 article is to describe the role of Barrett's endoscopic therapy (BET) in patients with Barrett's esop
38 ion of esophageal neoplasia enables curative endoscopic therapy, but the current diagnostic standard
39 cation, magnetic sphincter augmentation, and endoscopic therapies can benefit patients with well-char
40  to medical treatment with beta-blockers and endoscopic therapy can be managed by variceal decompress
41 ett esophagus and dysplasia or early cancer, endoscopic therapy consisting of resection and ablation
42  to current guidelines, and use of drugs and endoscopic therapy (D+E) or p-TIPS was based on individu
43                                              Endoscopic therapy (Deflux) has demonstrated moderate su
44    We assessed trends in treatment; compared endoscopic therapy, esophagectomy, chemoradiation, and n
45    There has been an increase in interest in endoscopic therapy (ET) for intramucosal (T1a) or submuc
46 g stigmata of recent hemorrhage and need for endoscopic therapy, even when tested in an external pati
47 orporeal shockwave lithotripsy combined with endoscopic therapy failed to benefit patients with calci
48 ry was necessary in 12 patients (3.7%) after endoscopic therapy failed.
49 red in patients in whom the first attempt at endoscopic therapy fails.
50    Research and clinical experience with the endoscopic therapies for Barrett's esophagus continue to
51 garding the durability and role of different endoscopic therapies for dysplastic Barrett's oesophagus
52                                              Endoscopic therapies for gastroesophageal reflux disease
53 nt for development of medical, surgical, and endoscopic therapies for GERD.
54                                              Endoscopic therapy for achalasia should not be used unle
55                                   POEM is an endoscopic therapy for achalasia with a shorter hospital
56 m toxin injection is the most common initial endoscopic therapy for achalasia, most likely due to its
57 c myotomy (POEM) is an increasingly utilized endoscopic therapy for achalasia.
58 rcinoma (IMC) in light of recent advances in endoscopic therapy for Barrett's esophagus.
59 ts with HCC and liver cirrhosis who received endoscopic therapy for EV bleeding between 2017 and 2022
60 ween treatment groups and that the choice of endoscopic therapy for EVH must still rely on clinical g
61 ial recommendations of the AGA Institute on "Endoscopic Therapy for Gastroesophageal Reflux Disease."
62 anding of the indications and limitations of endoscopic therapy for HGD and IMC permits a tailored ap
63 py for HGD is preferred to surveillance, (6) endoscopic therapy for HGD is preferred to surgery, (7)
64 opy is necessary for accurate diagnosis, (5) endoscopic therapy for HGD is preferred to surveillance,
65 gical intervention should be considered over endoscopic therapy for long-term treatment of patients w
66 dose intravenous proton pump inhibitor after endoscopic therapy for peptic ulcer bleeding has been re
67                                       Use of endoscopic therapy for T1 esophageal cancer has increase
68 f the notable advances over the past year in endoscopic therapy for the esophagus.
69                       No rebleeding followed endoscopic therapy for the ulcers.
70                                              Endoscopic therapy for UGIB in a resource-poor setting s
71                   Patients who rebleed after endoscopic therapy for ulcer hemorrhage should be treate
72              The overall rebleeding rate for endoscopic therapy for varices was 16.7%.
73 performed of the initial 40 patients who had endoscopic therapy from 2001 to 2010 at 1 center by 1 ph
74                              Patients in the endoscopic therapy group underwent endoscopic clot remov
75                              Patients in the endoscopic therapy group were less likely to undergo sur
76 g occurred in 5 of 61 (8.2%) patients in the endoscopic therapy group, compared with 21 of 85 (24.7%)
77 up period, none of the patients who received endoscopic therapy had a pseudocyst recurrence, compared
78      Adding proton pump inhibitors (PPIs) to endoscopic therapy has become the mainstay of treatment
79                                              Endoscopic therapy has been employed for early-stage les
80 inese patients remains poorly understood and endoscopic therapy has not been well established.
81                                              Endoscopic therapies have a role in temporizing active v
82                                              Endoscopic therapies have become an indispensable modali
83                                   While some endoscopic therapies have been shown to improve glycemic
84 ents in the treatment of these sequelae, new endoscopic therapies have emerged to treat gastroesophag
85                              Developments in endoscopic therapy have resulted in a major shift in the
86                                              Endoscopic therapy improves the outcome of nonvariceal u
87 ch of data regarding the reported benefit of endoscopic therapies in GERD.
88 ctice advice statements regarding the use of endoscopic therapies in treating patients with non-varic
89 ntion (median, 178 days) revealed successful endoscopic therapy in 43 (81%) and persistence of WOPN i
90 es transfusion requirements and the need for endoscopic therapy in patients with angiodysplasia-relat
91 re recommended, and clips are suggested, for endoscopic therapy in patients with high-risk stigmata.
92                                     Advanced endoscopic therapies including mucosectomy or photodynam
93         Promising advances have been made in endoscopic therapy, including formalin, neodymium/yttriu
94                        Over a decade, use of endoscopic therapy increased from 12.7% to 33.6%, wherea
95                                              Endoscopic therapy is an appropriate option and recent e
96                                              Endoscopic therapy is appropriate for treating chronic p
97                                              Endoscopic therapy is effective in removing more than 80
98                                              Endoscopic therapy is emerging as an alternative to surg
99                                              Endoscopic therapy is highly effective and safe for pati
100 esectable disease and a favorable prognosis; endoscopic therapy is inappropriate.
101 ization of high-risk ulcers after successful endoscopic therapy is not encouraged.
102                                              Endoscopic therapy is now being proposed as a viable tre
103                                              Endoscopic therapy is superior to medical therapy for pr
104 diagnosed, treated, or palliated with timely endoscopic therapy, it is appropriate to consider endosc
105        Four Eras separated by the dates when endoscopic therapy (January 1981), liver transplantation
106               The sequential introduction of endoscopic therapy, liver transplantation, and TIPS has
107 tered during the past 2 decades during which endoscopic therapy, liver transplantation, and TIPS have
108 ve of this study was to assess the impact of endoscopic therapy, liver transplantation, and transjugu
109                                              Endoscopic therapy may be a viable management option for
110         However, there is some evidence that endoscopic therapy may be successful in benign disease a
111                                              Endoscopic therapy might be useful in some patients, but
112 phagogastroduodenoscopy (EGD) or their first endoscopic therapy of early neoplastic BE, from April 20
113 were also published, as well as surgical and endoscopic therapy of pancreatitis.
114 hy in the evaluation of biliary disease, and endoscopic therapy of postoperative liver transplantatio
115                   In contrast, the impact of endoscopic therapy on natural history remains unresolved
116 and should be factored into the decision for endoscopic therapy or esophagectomy
117 herent clot is controversial and may include endoscopic therapy or medical therapy.
118  patients with GERD to treatment with either endoscopic therapy or surgery according to the size of h
119 ancer and low risk of lymph node metastasis, endoscopic therapy or surgery alone is potentially curat
120  using EPCS mainly as salvage for failure of endoscopic therapy or TIPS is not supported by the defin
121 : 3.57) with decreased survival, compared to endoscopic therapy (P < 0.01).
122 lcer hemorrhage should be treated by further endoscopic therapy, rather than urgent surgery.
123 h high-risk stigmata who have had successful endoscopic therapy receive high-dose proton-pump inhibit
124                          Use of preoperative endoscopic therapy remains common and has resulted in mo
125                      BEST PRACTICE ADVICE 1: Endoscopic therapy should achieve hemostasis in the majo
126                                              Endoscopic therapy should be performed on actively bleed
127                                              Endoscopic therapy should become the standard of care fo
128 fication in responders and non-responders to endoscopic therapy showed that non-responders had signif
129                                              Endoscopic therapy through transmural drainage of WON ma
130                                Compared with endoscopic therapy, TIPS leads to lower recurrent varice
131 We analyzed data from a multicenter study of endoscopic therapy to identify factors associated with p
132                                              Endoscopic therapy was ain 90.5% of the cases.
133                                              Endoscopic therapy was applied using the heater probe fo
134 ccurrence of recurrent EV bleeding requiring endoscopic therapy was investigated as the outcome.
135                              In 2002 several endoscopic therapies were reintroduced or modified.
136                           Pre-endoscopic and endoscopic therapy were performed according to standard
137 risk bleeding peptic ulcers after successful endoscopic therapy were randomly assigned as oral lansop
138 overed at an early stage can be treated with endoscopic therapy, whereas advanced cancers are primari
139 the future, the less invasive alternative of endoscopic therapy will need to be balanced against the
140 group B) and controls only received standard endoscopic therapies with only CBD stenting (group A).
141 achieving hemostasis for patients who failed endoscopic therapy with epinephrine injection, clip, or

 
Page Top